Dynavax Technologies stock (US2681581009): Former CCO joins ARS Pharma as president

Dynavax Technologies' ex-Chief Commercial Officer Donn Casale appointed president at ARS Pharmaceuticals, highlighting his role in building U.S. operations at Dynavax before its Sanofi acquisition.

Donn Casale, who most recently served as Chief Commercial Officer at Dynavax Technologies, has been appointed president of ARS Pharmaceuticals. In his role at Dynavax, Casale built the U.S. commercial infrastructure and helped scale operations ahead of the company's acquisition by Sanofi, according to BioTuesdays as of 05/13/2026.

This leadership move at ARS Pharma underscores Casale's expertise in commercializing biotech products, a skill honed during Dynavax's growth phase. Dynavax, known for its immunology-focused therapies, was acquired by Sanofi, with shares delisted following a cash merger where shareholders received $15.50 per share, per Robinhood as of 05/13/2026. The news reflects ongoing talent mobility in the biotech sector.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Dynavax Technologies Corporation
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Immunology, vaccines
• Key revenue drivers: HEPLISAV-B vaccine
• Home exchange/listing venue: Nasdaq (DVAX, delisted)
• Trading currency: USD

Dynavax Technologies: core business model

Dynavax Technologies specialized in developing novel vaccines using its proprietary Toll-like Receptor 9 agonist, CpG 1018, as an adjuvant to boost immune responses. The company's flagship product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the FDA for adults aged 18 and older, offering higher seroprotection rates compared to standard vaccines. Dynavax focused on immunology and infectious diseases, with CpG 1018 also used in partnerships for other vaccines.

Following commercial launch, Dynavax built U.S. infrastructure under leaders like Casale, driving HEPLISAV-B uptake among high-risk groups. The model emphasized targeted marketing to healthcare providers and payers, achieving key reimbursement wins. This positioned Dynavax for acquisition by Sanofi, integrating its assets into a larger portfolio.

Main revenue and product drivers for Dynavax Technologies

HEPLISAV-B generated the bulk of revenue, with sales ramping post-2017 FDA approval. In Q4 2023, reported January 9, 2024, net product revenue reached $71.8 million, up 35% year-over-year, per company filings. CpG 1018 licensing deals, including with Sanofi for shingles and other vaccines, provided milestone and royalty streams.

U.S. market penetration was key, with over 90% of sales from HEPLISAV-B domestically. Dynavax's strategy targeted dialysis centers and high-risk adults, where compliance advantages drove adoption. Post-acquisition, these drivers now bolster Sanofi's vaccine lineup.

Industry trends and competitive position

The hepatitis B vaccine market, valued at $8.5 billion globally in 2023 per Statista as of 2024, sees demand from rising chronic cases in the U.S. Dynavax differentiated via faster protection, competing with GSK's Engerix-B and VBI Vaccines' offerings. Adjuvant tech like CpG positions it ahead in next-gen vaccines amid post-COVID immunology focus.

Why Dynavax Technologies matters for US investors

Dynavax's Nasdaq listing (DVAX) and U.S.-centric revenue made it a pure-play biotech for American portfolios. Its $15.50/share Sanofi buyout delivered value amid M&A wave in immunology, relevant for U.S. investors tracking vaccine sector consolidation and adjuvants' role in mRNA enhancements.

Conclusion

The appointment of Dynavax alum Donn Casale at ARS Pharma highlights the lasting impact of the company's commercial expertise post-Sanofi acquisition. Investors monitoring biotech leadership shifts note such moves signal sector maturation. Dynavax's legacy in adjuvants continues through integrated operations, with U.S. vaccine demand sustaining relevance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.